维康药业(300878) - 2025 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit of approximately -24,500 million CNY for the year 2025, representing a decline of 66.18% compared to the previous year's net profit of -17,000 million CNY [4]. - The net profit after deducting non-recurring gains and losses is also projected to be -24,500 million CNY, showing a slight decrease of 2.54% from the previous year's adjusted net profit of -23,893.64 million CNY [4]. Factors Affecting Profit - The decline in profit is attributed to high fixed asset depreciation and a provision for fixed asset impairment of 45.55 million CNY [6]. - The company experienced a decrease in product sales prices and lower-than-expected sales volumes, leading to a decline in operating revenue and gross margin [6]. - A provision for inventory impairment of 30.39 million CNY was made due to some inventory nearing expiration [6]. Financial Reporting - The financial data presented is preliminary and has not yet been audited, with final figures to be disclosed in the 2025 annual report [8].